Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
Striker Neurovascular PRODUCTOS


12 septiembre 2017

CIRCULATION. Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis

Tom Adriaenssens, Michael Joner, Thea C. Godschalk, Nikesh Malik, Fernando Alfonso, Erion Xhepa, Dries De Cock, Kenichi Komukai, Tomohisa Tada, Javier Cuesta, Vasile Sirbu, Laurent J. Feldman, Franz-Josef Neumann, Alison H. Goodall, Ton Heestermans, Ian Buysschaert, Ota Hlinomaz, Ann Belmans, Walter Desmet, Jurrien M. ten Berg, Anthony H. Gershlick, Steffen Massberg, Adnan Kastrati, Giulio Guagliumi and Robert A. Byrne

Background: Stent thrombosis (ST) is a serious complication following coronary stenting. Intravascular optical coherence tomography (OCT) may provide insights into mechanistic processes leading to ST. We performed a prospective, multicenter study to evaluate OCT findings in patients with ST.

01 noviembre 2017

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. Predicting Subclinical Atherosclerosis in Low-Risk Indivdualis: Ideal Cardiovascular Health Score and Fuster-BEWAT Score

Juan Miguel Fernández-Alvira, Valentín Fuster, Stuart Pocock, Javier Sanz, Leticia Fernández-Friera, Martín Laclaustra, Rodrigo Fernández-Jiménez, José Mendiguren, Antonio Fernández-Ortiz, Borja Ibáñez and Héctor Bueno

Background: The ideal cardiovascular health score (ICHS) is recommended for use in primary prevention. Simpler tools not requiring laboratory tests, such as the Fuster-BEWAT (blood pressure [B], exercise [E], weight [W], alimentation [A], and tobacco [T]) score (FBS), are also available.

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Transcatheter Device Closure of Atrial Septal Defects

John Moore, Sanjeet Hegde, Howaida El-Said, Robert Beekman III, Lee Benson, Lisa Bergersen, Ralf Holzer, Kathy Jenkins, Richard Ringel, Jonathan Rome, Robert Vincent, Gerard Martin and ACC IMPACT Steering Committee

This review discusses the current safety issues related to U.S. Food and Drug Administration approved atrial septal defect devices and proposes a potential avenue to gather additional safety data including factors, which may be involved in device erosion.

01 septiembre 2017

JACC: CARDIOVASCULAR INTERVENTIONS. Relationships Among Conduit Type, Pre-Stenting, and Outcomes in Patients Undergoing Transcatheter Pulmonary Valve Replacement in the Prospective North American and European Melody Valve Trials

Allison K. Cabalka, William E. Hellenbrand, Andreas Eicken, Jacqueline Kreutzer, Robert G. Gray, Lisa Bergersen, Felix Berger, Aimee K. Armstrong, John P. Cheatham, Evan M. Zahn and Doff B. McElhinney

Background: Stent fracture (SF) and right ventricular outflow tract (RVOT) reintervention are among the most important adverse outcomes after TPVR using the Melody valve (Medtronic, Minneapolis, Minnesota). The conduit environment and conduit preparation practices vary among patients who undergo TPVR.

05 septiembre 2017

CIRCULATION. Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction])

Sivabaskari Pasupathy, Rosanna Tavella, Suchi Grover, Betty Raman, Nathan E.K. Procter, Yang Timothy Du, Gnanadevan Mahadavan, Irene Stafford, Tamila Heresztyn, Andrew Holmes, Christopher Zeitz, Margaret Arstall, Joseph Selvanayagam, John D. Horowitz and John F. Beltrame

Background: Contemporary ST-segment–elevation myocardial infarction management involves primary percutaneous coronary intervention, with ongoing studies focusing on infarct size reduction using ancillary therapies. N-acetylcysteine (NAC) is an antioxidant with reactive oxygen species scavenging properties that also potentiates the effects of nitroglycerin and thus represents a potentially beneficial ancillary therapy in primary percutaneous coronary intervention. The NACIAM trial (N-acetylcysteine in Acute Myocardial Infarction) examined the effects of NAC on infarct size in patients with ST-segment–elevation myocardial infarction undergoing percutaneous coronary intervention.

05 septiembre 2017

CIRCULATION. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)

J. Donald Easton , Maria Aunes , Gregory W. Albers , Pierre Amarenco , Sara Bokelund-Singh , Hans Denison , Scott R. Evans , Peter Held , Marianne Jahreskog , Jenny Jonasson , Kazuo Minematsu , Carlos A. Molina , Yongjun Wang , K.S. Lawrence Wong , S. Claiborne Johnston , and For the SOCRATES Steering Committee and Investigators , Sebastiá F. Ameriso , Geoffrey Donnan , Robin Lemmens , Ayrton Massaro , Ekaterina Titianova , Michael D. Hill , Pablo Lavados , David Skoloudik , Joachim Röther , Szegedi Norbert , Giancarlo Agnelli , Natan Bornstein , Norio Tanahashi , Angel Arauz Góngora , Edwin Pretell , Maria Cristina Z. San Jose , Anna Czlonkowska , Ovidiu Bajenaru , Ludmila Stakhovskaya , Miroslav Brozman , Jong-Sung Kim , Nils Wahlgren , Patrik Michel , Tsong Hai Lee , Nijasri Charnnarong Suwanwela , Kursad Kutluk , Sergii Moskovko , Scott Kasner , Daniel Laskowitz , Wayne Clark , Huy Thang Nguyen , Sebastian Ameriso , Sandra Lepera

Background: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)–defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH).

03 octubre 2017

CIRCULATION. Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease

David E. Kandzari , Pieter C. Smits , Michael P. Love , Ori Ben-Yehuda , Shmuel Banai , Simon D. Robinson , Michael Jonas , Ran Kornowski , Rodrigo Bagur , Andres Iniguez , Haim Danenberg , Robert Feldman , Rajiv Jauhar , Harish Chandna , Manish Parikh , Gidon Y. Perlman , Mercedes Balcells , Peter Markham , Melek Ozgu Ozan , Philippe Genereux , Elazer R. Edelman , Martin B. Leon and Gregg W. Stone

Background: The safety and efficacy of a novel cobalt alloy-based coronary stent with a durable elastomeric polymer eluting the antiproliferative agent ridaforolimus for treatment of patients with coronary artery disease is undetermined.

24 octubre 2017

CIRCULATION. The Fluid Mechanics of Transcatheter Heart Valve Leaflet Thrombosis in the Neosinus

Prem A. Midha, Vrishank Raghav, Rahul Sharma, Jose F. Condado, Ikechukwu U. Okafor, Tanya Rami, Gautam Kumar, Vinod H. Thourani, Hasan Jilaihawi, Vasilis Babaliaros, Raj R. Makkar and Ajit P. Yoganathan

Background: Transcatheter heart valve (THV) thrombosis has been increasingly reported. In these studies, thrombus quantification has been based on a 2-dimensional assessment of a 3-dimensional phenomenon.

21 noviembre 2017

CIRCULATION. Modeling Major Adverse Outcomes of Pediatric and Adult Patients With Congenital Heart Disease Undergoing Cardiac Catheterization

Natalie Jayaram, John A. Spertus, Kevin F. Kennedy, Robert Vincent, Gerard R. Martin, Jeptha P. Curtis, David Nykanen, Phillip M. Moore and Lisa Bergersen

Background: Risk standardization for adverse events after congenital cardiac catheterization is needed to equitably compare patient outcomes among different hospitals as a foundation for quality improvement. The goal of this project was to develop a risk-standardization methodology to adjust for patient characteristics when comparing major adverse outcomes in the NCDR’s (National Cardiovascular Data Registry) IMPACT Registry (Improving Pediatric and Adult Congenital Treatment).

28 noviembre 2017

CIRCULATION. Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Insights from the National Cardiovascular Data Registry Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry

Matthew C. Hyman, Sreekanth Vemulapalli, Wilson Y. Szeto, Amanda Stebbins, Prakash A. Patel, Roland A. Matsouaka, Howard C. Herrmann, Saif Anwaruddin, Taisei Kobayashi, Nimesh D. Desai, Prashanth Vallabhajosyula, Fenton H. McCarthy, Robert Li, Joseph E. Bavaria and Jay Giri

Background: Conscious sedation is used during transcatheter aortic valve replacement (TAVR) with limited evidence as to the safety and efficacy of this practice.

19 diciembre 2017

CIRCULATION. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)

Erin A. Bohula , Stephen D. Wiviott , Robert P. Giugliano , Michael A. Blazing , Jeong-Gun Park , Sabina A. Murphy , Jennifer A. White , Francois Mach , Frans Van de Werf , Anthony J. Dalby , Harvey D. White , Andrew M. Tershakovec , Christopher P. Cannon and Eugene Braunwald

Background: Patients who experience an acute coronary syndrome are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary syndrome. We investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), with a focus on patients with a stroke before randomization.

06 junio 2017

CIRCULATION. Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH)

Ilka Ott, Salvatore Cassese, Philipp Groha, Birgit Steppich, Martin Hadamitzky, Tareq Ibrahim, Sebastian Kufner, Karl Dewitz, Regina Hiendlmayer, Karl-Ludwig Laugwitz, Heribert Schunkert, Adnan Kastrati and Massimiliano Fusaro

Background: Atherosclerosis in the superficial femoral artery is common in patients suffering from peripheral artery disease. Paclitaxel-eluting balloon (PEB) angioplasty, stenting, and directional atherectomy (DA) have provided new options for the treatment of superficial femoral artery disease; however, the comparative efficacy of these interventional strategies remains uncertain.

06 junio 2017

CIRCULATION. Fractional Flow Reserve and Cardiac Events in Coronary Artery Disease: Data From a Prospective IRIS-FFR Registry (Interventional Cardiology Research Incooperation Society Fractional Flow Reserve)

Jung-Min Ahn , Duk-Woo Park , Eun-Seok Shin , Bon-Kwon Koo , Chang-Wook Nam , Joon-Hyung Doh , Jun Hong Kim , In-Ho Chae , Jung-Han Yoon , Sung-Ho Her , Ki-Bae Seung , Woo-Young Chung , Sang-Yong Yoo , Jin Bae Lee , Si Wan Choi , Kyungil Park , Taek Jong Hong , Sang Yeub Lee , Minkyu Han , Pil Hyung Lee , Soo-Jin Kang , Seung-Whan Lee , Young-Hak Kim , Cheol Whan Lee , Seong-Wook Park and Seung-Jung Park

Background: We evaluated the prognosis of deferred and revascularized coronary stenoses after fractional flow reserve (FFR) measurement to assess its revascularization threshold in clinical practice.

15 agosto 2017

CIRCULATION. Predictors and Association With Clinical Outcomes of the Changes in Exercise Capacity After Transcatheter Aortic Valve Replacement

Omar Abdul-Jawad Altisent , Rishi Puri , Ander Regueiro , Chekrallah Chamandi , Tania Rodriguez-Gabella , Maria del Trigo , Francisco Campelo-Parada , Thomas Couture , Josep Ramon Marsal , Mélanie Côté , Jean-Michel Paradis , Robert DeLarochellière , Daniel Doyle , Siamak Mohammadi , Eric Dumont and Josep Rodés-Cabau

Background: At present, there are no objective data specifically examining the clinical impact of variations in exercise capacity post–transcatheter aortic valve replacement (TAVR). We describe the changes in exercise capacity between baseline and 6 months post-TAVR, and ascertain factors associated with and clinical implications of a lack of improvement in exercise capacity post-TAVR.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.